Text with Title
Evaluate Epi provides unique insights on the commercial value of an indication as well as patient populations, bringing together Evaluate’s expertise in consensus forecasts with a highly granular epidemiology database.
Evaluate Epi combines a transparent and validated methodology, along with a detailed patient segmentation, giving you the tools to uncover commercial opportunities that meet targeted clinical needs across multiple regions.
Designed by expert epidemiologists, our granular coverage includes over 220 diseases and 9,000 sub-populations to give you deeper insights for better commercial decisions.
“ Evaluate is not a package I can do without... It's an absolute timesaver, and if you're saving time you're saving money. ”
ANTHONY M, SENIOR DIRECTOR, COMPETITIVE INTELLIGENCE & PROSPECTION, NOVARTIS
“ Evaluate Epi helps us understand the targets and mechanisms driving consensus forecasts, and how crowded the market may be, so we can identify development opportunities. ”
NATHAN D, FORMER SENIOR VP, CORPORATE DEVELOPMENT, RUBIUS THERAPEUTICS